A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors

Phase 2

• Conditions: Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer
• Interventions: Drug: TQ-B3525 tablet

• Registration Number: NCT04836663
• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Brief Summary

This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with recurrent / metastatic advanced endometrial cancer, cervical cancer and ovarian cancer with PIK3CA and / or PIK3R1 / 2 gene-altered (mutation or amplification). Endometrial cancer, cervical cancer and ovarian cancer are divided into three cohorts, each cohort administrated TQ-B3525 tablet orally once a day.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-04
• Study First Submitted: 2021-04-06
• Study First Submitted QC: 2021-04-06
• Study First Posted: 2021-04-08
• Study Start: 2021-04-23
• Last Update Submitted: 2021-05-27
• Last Update Posted: 2021-06-01
• Primary Completion: 2022-09-30
• Study Completion: 2022-12-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 90

Inclusion Criteria

• 1. Pathologically confirmed malignant gynecological neoplasm. 2. Has PIK3CA and/or PIK3R1/2 Gene-altered. 3.Unresectable, locally advanced recurrent and/or metastatic tumors, has at least 1 measurable lesion.

  4.Failed with standard treatment or has no effective treatment. 5. 18 years and older, Eastern Cooperative Oncology Group(ECOG) performance status score of 0 to 1, Life expectancy ≥ 3 months.

  6. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration.

  7.Understood and signed an informed consent form.

Exclusion Criteria

• 1.Has untreated or active central nervous system metastases. 2.Has diagnosed and/or treated additional malignancy within 3 years prior to the first administration.

  3. Insufficient hematopoietic function of bone marrow. 4. Dysfunction of liver and kidney. 5. Bleeding risk. 6. Dysfunction of gastrointestinal tract. 7.Dysfunction of heart and cerebral vessels. 8.Has received PI3K, AKT, mTOR inhibitor. 9.Has participated in other clinical trails within 30 days. 10. Has received surgery, or unhealed wounds within 4 weeks before the first administration.

  4. Has received organ grafting, or hematopoietic stem cell transplantation within 60 days before the first administration, or host versus graft reaction.

  5. The patients required immunosuppressor, or the whole-body, or absorbable local hormone therapy for immunosuppression purposes and continued to use within 7 days before the initial administration (daily dose of glucocorticoid <10 mg, except metacortandracin or other therapeutic hormones and so on).

  6. Has active infections. 14. Has human immunodeficiency virus (HIV). 15. Pregnant or lactating women. 16. Has psychotropic substances abuse or a mental disorder. 17. Has other conditions that make it inappropriate for the patient to be enrolled based on investigator's opinion.

  7. Patient's compliance is inadequate.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
TQ-B3525 tablet	TQ-B3525 tablet	-

Primary Outcome Measures

Name	Time	Method
Overall response rate (ORR) assessed by Independent Review Committee	up to 48 weeks	Percentage of participants achieving complete response (CR) and partial response (PR) based on IRC.

Secondary Outcome Measures

Name	Time	Method
Duration of disease remission (DOR)	up to 48 weeks	The time from the first evaluation of the subject as CR or PR to the first evaluation of the subject as PD or death (whichever occurs first).
DOR rate (≥ 6 months) (percentage of subjects with disease remission duration ≥ 6 months)	up to 48 weeks	The percentage of subjects achieving CR or PR was recorded for the first time to 6 months after the first time of objective tumor progression or death due to any cause (whichever occurred first) was recorded.
Progression-free survival (PFS)	up to 48 weeks	PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause.
Overall survival (OS)	up to 72 weeks	OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.
Overall response rate (ORR) assessed by Investigator	up to 48 weeks	Percentage of participants achieving complete response (CR) and partial response (PR) assessed by investigator.
Disease control rate（DCR）	up to 48 weeks	Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).

Trial Locations

Locations (5)

Nanjing Drum Tower Hospital; 🇨🇳 Nanjing, Jiangsu, China

Sir Run Run Shaw Hospital Medical School Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China

Fudan University Shanghai Cancer Center; 🇨🇳 Shanghai, Shanghai, China

The First People's Hospital of Changzhou; 🇨🇳 Changzhou, Jiangsu, China

Gynecology Hospital of Fudan University; 🇨🇳 Shanghai, Shanghai, China